Tessera Therapeutics

Tessera Therapeutics, a gene editing startup, has announced the layoff of 90 employees as it embarks on its first clinical study. This decision comes as part of the company's strategic adjustments during a critical phase of development. The layoffs reflect the company's efforts to streamline operations and focus resources on advancing its clinical initiatives. While the specific departments affected were not detailed, this move indicates a significant shift in the company's workforce strategy. The layoffs highlight the challenges faced by startups in the competitive biotech landscape.

Tessera Therapeutics, a biotech company based in Somerville, has announced layoffs affecting 35% of its workforce. This decision comes as part of a restructuring effort aimed at streamlining operations and reducing costs. The layoffs are expected to impact approximately 35 employees, reflecting the company's response to current market conditions and financial pressures. The company has not specified the exact departments affected by these cuts. This move highlights the ongoing challenges faced by biotech firms in the current economic climate.

Tessera Therapeutics, a biotech company based in Somerville, Massachusetts, has announced plans to lay off more than 80 employees this year. The layoffs are part of a broader restructuring effort as the company adjusts its workforce. Specific details regarding the departments affected or the reasons behind the layoffs were not disclosed. The company is navigating challenges in the biotech sector, which has seen various companies making similar workforce reductions. The exact timing of these layoffs has yet to be determined.